Volume | 996,788 |
|
|||||
News | - | ||||||
Day High | 91.67 | Low High |
|||||
Day Low | 86.10 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Blueprint Medicines Corporation | BPMC | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
90.86 | 86.10 | 91.67 | 86.82 | 90.50 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
16,665 | 996,788 | $ 89.61 | $ 89,321,556 | - | 41.54 - 101.00 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
16:20:00 | 28 | $ 86.82 | USD |
Blueprint Medicines (BPMC) Options Flow Summary
Blueprint Medicines Corporation Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
5.31B | 61.23M | - | 249.38M | -506.98M | -8.28 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Blueprint Medicines News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical BPMC Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 92.12 | 92.84 | 86.10 | 89.77 | 681,124 | -5.30 | -5.75% |
1 Month | 88.98 | 101.00 | 80.42 | 91.70 | 950,046 | -2.16 | -2.43% |
3 Months | 90.00 | 101.00 | 72.24 | 86.41 | 800,415 | -3.18 | -3.53% |
6 Months | 50.40 | 101.00 | 43.89 | 74.31 | 796,259 | 36.42 | 72.26% |
1 Year | 44.88 | 101.00 | 41.54 | 65.71 | 704,938 | 41.94 | 93.45% |
3 Years | 104.58 | 117.86 | 37.82 | 67.29 | 640,129 | -17.76 | -16.98% |
5 Years | 85.99 | 125.61 | 37.82 | 71.65 | 599,375 | 0.83 | 0.97% |
Blueprint Medicines Description
Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants. |